Most pharma companies want to ensure their drugs are effective for the greatest portion of the patient populations they are designed to treat. An important part of designing effective clinical trials should be understanding the personal and logistical challenges these patients face. The digitization and aggregation of this real-world data (RWD) has led to analysis and insights that are helping pharma companies uncover these social drivers of health (SDOH). If they have a better understanding of the challenges, pharma companies can plan clinical trial sites that are more convenient for patients. They can also build teams to better engage community stakeholders and build trust.<\/p>\n\n\n\n
A new eBook explores this topic through the patient experience of non-small cell lung cancer (NSCLC) patients. It examines how a significant number of patients with non-small cell lung cancer miss out on optimal care due to gaps in biomarker testing, socioeconomic barriers, and incomplete patient journey data. The eBook also explores how RWD strategies are reshaping the NSCLC patient journey and how these insights can make clinical trials more diverse and inclusive.<\/p>\n\n\n\n
By understanding and identifying these \u201cblind spots\u201d in the patient journey, life science companies can:<\/p>\n\n\n\n
\u2022 Mitigate SDOH barriers<\/p>\n\n\n\n
\u2022 Expand their addressable patient population<\/p>\n\n\n\n
\u2022 Improve treatment adherence<\/p>\n\n\n\n
\u2022 Drive greater market uptake and revenue<\/p>\n\n\n\n
To download the eBook Eliminating Blind Spots in the Non-Small Cell Lung Cancer Patient Journey with RWD<\/em><\/strong>, fill in the form below:<\/p>\n\n\n